- Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. *Acta Psychiatr Scand* 2000; **101**: 323–9.
- 27 Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating schizophrenic deficit syndrome. *Schizophrenia Bull* 1984; 10: 388–98.
- 28 Tohen M, Hennen J, Zarate Jr CM, Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of first episode major affective disorder with psychotic features. Am J Psychiatry 2000; 157: 220–8.
- 29 Mallinckrodt C, Watkin J, Molenberghs G, Carroll R. Choice of the primary analysis in longitudinal clinical trials. *Pharm Stat* 2004; 3: 161–9.
- 30 Gueorgieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004; 61: 310–7.
- 31 Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology* 1990; 1: 43–6.
- 32 Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. *Neuropsychopharmacology* 2011; 36: 375–89.
- 33 Nierenberg AA, Sylvia LG, Leon AC, Reilly-Harrington NA, Shesler LW, McElroy SL, et al. Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. Clin Trials 2014; 11: 114–27.
- 34 Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B, Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). *J Clin Psychiatry* 2011; 72: 1452–64.

- 35 Suppes T, Vieta E, Gustafsson U, Ekholm B. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Depress Anxiety 2013; 30: 1089–98.
- 36 Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA, LitCar G. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144–51.
- 37 Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. *Neurosci Biobehav Rev* 2011; 35: 804–17.
- 38 Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand 2016; 134: 91–103.
- 39 Calabrese JR, Vieta E, El-Mallakh R, Findling RL, Youngstrom EA, Elhaj O, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004; 56: 957–63.
- 40 Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009; 119: 22–7.
- 41 Schalkwijk S, Undurraga J, Tondo L, Baldessarini RJ. Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. *Int J Neuropsychopharmacol* 2014; 17: 1343–52.
- 42 Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387: 1561–72.



Me of You

Qasim Ijaz

So here I am in the middle way still grappling with the void, as fresh as spring flowers, as jaded as autumn leaves of what belonged to you of us — now misted in time.

Your presence – confident and affirmative that sparked a thousand flames and turns of joy and wonder, now inhabits the sightless recesses of my mind and distant space – a chimera of half formed images and sounds, lost in abstracted pain and longing.

Tell me where do I begin to grieve . . . for what is left of me that belonged to you, stolen by a pitiless fate.

© Qasim Ijaz 2017. Reproduced with permission.

The British Journal of Psychiatry (2017) 210, 421. doi: 10.1192/bjp.bp.117.198713